Climb Bio, Inc.
CLYM
$1.74
$0.106.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.56M | 20.24M | 19.80M | 16.03M | 13.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.50M | 56.34M | 50.37M | 30.36M | 22.51M |
| Operating Income | -59.50M | -56.34M | -50.37M | -30.36M | -22.51M |
| Income Before Tax | -50.75M | -46.76M | -92.98M | -73.90M | -69.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.75 | -46.76 | -92.98 | -73.90 | -69.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.75M | -46.76M | -92.98M | -73.90M | -69.12M |
| EBIT | -59.50M | -56.34M | -50.37M | -30.36M | -22.51M |
| EBITDA | -25.52M | -10.66M | -- | -- | -- |
| EPS Basic | -0.76 | -0.70 | -2.38 | -2.13 | -2.13 |
| Normalized Basic EPS | -0.49 | -0.45 | -0.44 | -0.28 | -0.28 |
| EPS Diluted | -0.76 | -0.70 | -2.38 | -2.13 | -2.13 |
| Normalized Diluted EPS | -0.49 | -0.45 | -0.44 | -0.28 | -0.28 |
| Average Basic Shares Outstanding | 267.79M | 266.80M | 229.56M | 189.74M | 152.54M |
| Average Diluted Shares Outstanding | 267.79M | 266.80M | 229.56M | 189.74M | 152.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |